Posted by Shortstop on May 3, 2007, at 13:54:11
In reply to Re: Emsam article on Wall Street Journal Online, posted by ttee on May 3, 2007, at 13:31:33
Good point on the advertising hurdle, ttee. All the mandatory warnings would make the spot prohibitively expensive and hard to place. I doubt they'll lower the price, either, though. They're doing such low volume that they probably have to max out the margin on the small niche they have just to recoup costs. What they need is smart public relations. There should be articles in every health and general-interest publication out there, and the network medical reporters should be informing the public about "the depression patch" on The Today Show, Good Morning America and so on.
Does anyone know if Bristol-Myers is under any legal obligation to continue manufacturing the medication even if it doesn't make them much, or any, money? Or can they cut bait and discontinue it at any time?
poster:Shortstop
thread:755308
URL: http://www.dr-bob.org/babble/20070502/msgs/755528.html